Company Overview and News

0
Broker's call: DCB Bank (Buy)

2018-07-17 thehindubusinessline
We retain ‘buy’ on DCB Bank (DCBB) with target price at ₹215. First quarter (Q1) results of FY19 beat our estimates on both revenue and earnings front. Net interest margin (NIM) at 3.56 per cent declined 12 bps q-o-q and was well on the expected lines. While we foresee some improvement in NIM (especially in H2FY19), the overall trend will remain lower for FY19E (over FY18). Our calculation suggests employee productivity on rise; continued momentum will aid in increased profitability.
532772 DCBBANK

0
DCB Bank Q1 review: Muted earnings a short term blip, Buy for the long term

2018-07-17 moneycontrol
DCB Bank, a small-sized private sector bank, delivered sub-par earnings in the first quarter of FY19. Significant margin contraction and elevated operating expenses undermined its performance.
532772 DCBBANK

0
An evening walk down Dalal Street | Sensex ends over 200 points down, Nifty below 10,950; Tata Steel tanks 7%

2018-07-16 moneycontrol
A sharp selloff in the last hour of trade on Monday ensured that the market broke away from its positive momentum seen all through the last week. The Sensex managed to end the day over 200 points lower, while the Nifty gave up 11,000 as well as 10,950 and ended below the latter. A rise in wholesale inflation also weighed on indices.
532772 500470 TTST 500116 TATASTEEL TATLY IDBI DCBBANK 534809 PCJEWELLER

0
DCB Bank stock cracks 11% after weak operational performance, lower NIM in Q1

2018-07-16 moneycontrol
DCB Bank share price plunged 11 percent after reporting weakest ever operating profit growth in last eight quarters and net interest margin at 11-year low in Q1.
532772 DCBBANK

0
DCB Bank Limited - Press Release

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532772 DCBBANK

0
DCB Bank Limited - Investor Presentation

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532772 DCBBANK

0
DCB Bank Limited - Financial Result Updates

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532772 DCBBANK

0
DCB Bank Limited - Allotment of ESOP/ESPS

2018-07-14 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532772 DCBBANK

0
HUL results on Monday: Sentiment booster?

2018-07-13 thehindubusinessline
Most actively followed companies such as Bhansali Engineering Polymers, CCL Products (India) and DCB Bank will declare their first quarter results on Saturday. Hindustan Unilever will be the first firm from the FMCG category to declare its results for the April-June period on Monday. Apart from HUL, Sintex Plastics Technology, Opto Circuits (India), Jay Bharat Maruti and Maharashtra Scooters will also announce first quarter results on Monday.
OPTOCIRCUI HINDUNILVR JAYBARMARU 519600 532772 CCL 500052 MAHSCOOTER 500266 500696 532391 DCBBANK BEPL 520066

0
DCB Bank Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-07-11 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
532772 DCBBANK

0
DCB Bank gains 3% ahead of Q1 results on July 14

2018-07-09 moneycontrol
Shares of DCB Bank gained 3 percent intraday Monday ahead of its Q1FY19 results on July 14.
532772 DCBBANK

8
Will compulsory delivery impact F&O trading?

2018-06-29 thehindubusinessline
KS Badri Narayanan Be prepared to have enough money in your account if you want to trade in the 46 F&O stocks that have been moved to the compulsory delivery category by the NSE starting July. This follows the SEBI diktat in March to align the cash and derivative segments of the market, through physical settlement for all stock derivatives in a phased and calibrated manner. To start with, the NSE has initiated compulsory delivery in 46 stocks.
SRI 532939 SREINFRA GODREJIND 533096 UBL IDBI 532899 532712 532478 533106 JUSTDIAL GRANULES 535648 RCOM OIL 532482 KSCL DCBBANK RPOWER SIFLY 523756 ALNSE 500116 UBHOLDINGS 535322 SRIA UNBWY REPCOHOME 532772 ADANIPOWER 507458 500164 JSTQY

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...